NRAS and melanoma: Our analysis focused on melanoma cases driven by mutation of NRAS/BRAF genes as these are the most prevalent driver mutations in melanoma.1,2 When we examined the smaller number of wildtype NRAS/BRAF cases in the TCGA-SKCM dataset it was interesting to note that ICAM-1 mRNA transcript levels were not prognostic (Supplementary Fig. S7), directly contrasting the situation in NRAS/BRAF mutated melanoma where this marker is a strong prognosticator.